P/E RATIO: [FAIL]
The P/E of a company must be greater than 5 to eliminate weak companies, but not more than 3 times the current Market P/E because the situation is much too risky, and never greater than 43. Unfortunately the P/E ratio for SMED's is not available. Hence, no opinion can be rendered at the present time.
REVENUE GROWTH IN RELATION TO EPS GROWTH: [FAIL]
Revenue growth must not be substantially less than earnings growth. For earnings to continue to grow over time they must be supported by a comparable or better sales growth rate and not just by cost cutting or other non-sales measures. Unfortunately, we do not have sufficient data available for SMED. Therefore, no conculsion on this variable can be made at this time.
SALES GROWTH RATE: [PASS]
Another important issue regarding sales growth is that the rate of quarterly sales growth is rising. To evaluate this, the change from this quarter last year to the present quarter (29.17%) must be examined, and then compared to the previous quarter last year compared to the previous quarter (-11.21%) of the current year. Sales growth for the prior must be greater than the latter. For SMED this criterion has been met.
The earnings numbers of a company should be examined from various different angles. Three of these angles are stability in the trend of earnings, earnings persistence, and earnings acceleration. To evaluate stability, the stock has to pass the following four criteria.
CURRENT QUARTER EARNINGS: [FAIL]
The first of these criteria is that the current EPS be positive. SMED's EPS ($-0.04) fail this test.
QUARTERLY EARNINGS ONE YEAR AGO: [FAIL]
The EPS for the quarter one year ago must be positive. SMED's EPS for this quarter last year ($-0.07) fail this test.
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: [FAIL]
The growth rate of the current quarter's earnings compared to the same quarter a year ago must also be positive. SMED's growth rate of -42.86% fails this test.
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: [FAIL]
Compare the earnings growth rate of the past four quarters with long-term EPS growth rate. Earnings growth in the past 4 quarters should be at least half of the long-term EPS growth rate. A stock should not be considered if it posted several quarters of skimpy earnings. SMED's data is unavailable an hence an opinion cannot be rendered.
This strategy looks at the rate which earnings grow and evaluates this rate of growth from different angles. The 4 tests immediately following are detailed below.
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: [PASS]
If the growth rate of the prior three quarter's earnings, -146.15%, (versus the same three quarters a year earlier) is less than the growth rate of the current quarter earnings, -42.86%, (versus the same quarter one year ago) then the stock passes.
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: [FAIL]
Unfortunately, the data needed to evaluate SMED is not available at this time. Hence, the stock fails this criterion.
EARNINGS PERSISTENCE: [FAIL]
Companies must show persistent yearly earnings growth. To fulfill this requirement a company's earnings must increase each year for a five year period. SMED, whose annual EPS growth before extraordinary items for the previous 5 years (from the earliest to the most recent fiscal year) were -$0.24, -$0.18, $0.06, $0.08, and $0.00, fails this test.
LONG-TERM EPS GROWTH: [FAIL]
One final earnings test required is that the long-term earnings growth rate must be at least 15% per year. Unfortunately we do not have sufficient data available for SMED. Hence, no opinion can be given on this criterion.
TOTAL DEBT/EQUITY RATIO: [PASS]
A final criterion is that a company must not have a high level of debt. A high level of total debt, due to high interest expenses, can have a very negative effect on earnings if business moderately turns down. If a company does have a high level, an investor may want to avoid this stock altogether. SMED's Debt/Equity (11.08%) is not considered high relative to its industry (185.90%) and passes this test.